Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection

Am J Transplant. 2016 Apr;16(4):1332-3. doi: 10.1111/ajt.13711. Epub 2016 Mar 1.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • CTLA-4 Antigen / antagonists & inhibitors*
  • Graft Rejection / etiology*
  • Graft Survival
  • Humans
  • Kidney Failure, Chronic / complications
  • Kidney Failure, Chronic / surgery*
  • Kidney Transplantation / adverse effects*
  • Male
  • Melanoma / drug therapy*
  • Melanoma / etiology
  • Melanoma / secondary
  • Postoperative Complications*
  • Prognosis
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Risk Factors
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / etiology
  • Skin Neoplasms / pathology
  • Transplant Recipients

Substances

  • Antineoplastic Agents
  • CTLA-4 Antigen
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor